DRUG MANUFACTURERS - GENERAL

Nov 11, 2026

The State Street Health Care Select Sector SPDR ETF (XLV) reported a one-day net selling activity of $320.2 million on November 9, reducing all 60 of its positions. The largest sales by dollar value included Eli Lilly and Co (LLY) at $53.1 million, Johnson & Johnson (JNJ) at $31.9 million, and AbbVie Inc (ABBV) at $24.4 million. The fund, which manages $50.54 billion in assets, maintains a strong focus on large-cap healthcare stocks.

Nov 11, 2026

Johnson & Johnson (J&J) is planning to submit Caplyta to the FDA for a potential label expansion to include the treatment of manic episodes in bipolar type I. This move follows the success of Caplyta in a Phase III trial for bipolar mania. If approved, this expansion would broaden the therapeutic scope of Caplyta, which is already used to treat schizophrenia and depressive episodes associated with bipolar I or II disorder.

Nov 10, 2026

Freenome (NASDAQ: FRNM) held its first earnings call as a public company, reporting a total revenue of $183.5 million for Q3 2026, primarily due to FDA approval and commercial launch of Simple Screen CRC. The company raised $310 million through its NASDAQ IPO and is focused on expanding its AI-enabled cancer screening platform and product pipeline, including new lung cancer tests and strategic partnerships with Abbott and Roche. Freenome anticipates future growth through continued innovation in test development, aiming for additional single and multi-cancer tests, while also working to broaden reimbursement coverage.

Nov 10, 2026

Gilead Sciences (GILD) demonstrates a strong free cash flow yield of 6.6%, significantly above the S&P 500 median, indicating either a bargain or investor expectation of future contraction. While Gilead's cash flow has grown faster than its revenue, driven by strong HIV drug sales, a looming Medicare price cut for its top-selling drug Biktarvy in 2028 poses a risk to future cash growth. Investors should watch the company's free cash flow and net debt in its upcoming February 2027 report to assess its ability to manage debt and mitigate the impact of the price reduction.

Nov 10, 2026

Scholar Rock has agreed to sell its rare pediatric disease priority review voucher to BioNTech's U.S. unit for $205 million in cash. The FDA awarded the voucher in September when it approved Isembyld for spinal muscular atrophy. This sale price is near the top of the recent market for such vouchers, which allow for a six-month drug application review instead of the standard ten months.

Nov 10, 2026

Xilio Therapeutics announced its third-quarter 2026 financial results, highlighting significant pipeline advancements. The company dosed its first patient in a Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific, and is progressing two masked T Cell Engager programs, XTX602 and XTX701, toward IND applications in Q4 2027. Financially, Xilio reported $122.2 million in cash and cash equivalents, and a net loss of $5.9 million for the quarter, with an anticipated cash runway into Q1 2028.

Nov 10, 2026

Nxera Pharma has entered into an exclusive global licensing agreement with AbbVie for NXE0033744, an investigational oral EP4 receptor agonist for inflammatory bowel disease (IBD). The deal is valued at up to $1.47 billion, including a $100 million upfront payment and potential development and commercial milestone payments. NXE0033744, discovered using Nxera’s NxWave platform, aims to provide a differentiated mechanism of action for IBD patients by inducing anti-inflammatory effects and promoting mucosal healing.

Nov 9, 2026

A Phase 3 trial revealed that Johnson & Johnson and Protagonist Therapeutics' oral therapy, Icotyde, improved psoriatic arthritis symptoms. However, analysts suggest that AbbVie's injectable Skyrizi will likely maintain market dominance due to its higher efficacy, despite Icotyde offering a convenient oral option for patients who prefer to avoid injections. While Icotyde's efficacy was positive, it did not significantly differentiate itself from Skyrizi, which generated $17.56 billion globally in 2025.

Nov 9, 2026

Johnson & Johnson has released initial Phase I results for its combination of pasritamig and JNJ-9401, two bispecific antibodies aimed at stimulating the immune response against advanced prostate cancer. This dual-tumor-antigen-targeted bispecific antibody regimen is the first in prostate cancer to yield clinical trial results, indicating J&J's ambition to maintain a leading position in the field.

Nov 9, 2026

Genmab's petosemtamab, when added to Merck's Keytruda, significantly reduced the risk of death by 50% in 699 first-line head and neck cancer patients, regardless of their HPV status. This finding from the Phase 3 LiGeR-HN1 trial met both primary endpoints of overall survival and objective response rate. Analysts have hailed the results as "exceedingly positive" and "potentially practice-changing," highlighting a major milestone in treating recurrent or metastatic head and neck cancer.

Nov 9, 2026

The State Street Health Care Select Sector SPDR ETF (XLV) was a net seller of stocks last Thursday, offloading $212.6 million worth of equities across all 60 of its positions. Eli Lilly & Co (LLY) was the largest sale by dollar value, followed by Johnson & Johnson (JNJ) and AbbVie Inc (ABBV). The fund, which is entirely concentrated in the healthcare sector, did not add any new positions.

Nov 9, 2026

The article discusses the mixed results following AbbVie's $8.7 billion acquisition of Cerevel Therapeutics and Bristol Myers Squibb's $14 billion buyout of Karuna Therapeutics. While AbbVie's schizophrenia drug emraclidine failed Phase 2 studies, its Parkinson's drug Juvmo received FDA approval. Meanwhile, BMS's schizophrenia drug Cobenfy (KarXT) gained approval but has struggled with sales expectations and tolerability issues, leading analysts to conclude that a clear winner between the two neuro-focused acquisitions has yet to emerge.

Nov 9, 2026

AbbVie announced that its Allergan Aesthetics division conducted two clinical studies showing improved facial satisfaction among patients using GLP-1 weight-loss medications after receiving cosmetic treatments. These findings were presented at the American Society for Dermatologic Surgery's annual meeting.

Nov 8, 2026

Amgen has consistently raised its quarterly dividend since 2011, achieving a ninefold increase and compounding at about 16% annually. Despite this strong growth and solid coverage by free cash flow, the pace of dividend raises has slowed, with the latest increase being around 6%. The company faces challenges from patent cliffs and drug price controls, which could impact future dividend growth, even as debt declines and new drugs show strong performance.

Nov 7, 2026

AbbVie (ABBV) stock has seen significant growth but faces a potential headwind in 2027 due to IRA pricing on its psychiatry drug, Vraylar, a challenge the company has encountered before with Imbruvica. While Vraylar sales are still growing, investors are paying a high premium for AbbVie's earnings, making continued growth from other key drugs like Skyrizi and Rinvoq critical to offset the impending price impact. The company is actively fighting IRA selection for Botox, with a federal court ruling in its favor, though the matter is subject to appeal.

Nov 7, 2026

Alvotech (NASDAQ:ALVO) has been downgraded from a "hold" to a "sell" rating by Wall Street Zen. Despite this, other analysts have mixed views, with four "Buy" ratings and two "Sell" ratings, resulting in an average "Hold" and a consensus price target of $8.25. The company recently reported an EPS loss of $0.11, missing estimates, but exceeded revenue expectations with $106 million.

Nov 7, 2026

Regenxbio Inc (RGNX) is nearing significant regulatory milestones with potential approvals for sura-vec in wet AMD and RGX-202 for Duchenne. The company reported a strong cash position and outlined its strategy for BLA submissions and commercialization, despite facing competition and regulatory uncertainties. Key differentiators for its therapies include subretinal immune privilege for sura-vec and a robust manufacturing process and immune suppression regimen for RGX-202.

Nov 6, 2026

S&P Global Ratings has revised Boston Scientific Corp.'s outlook from stable to negative, citing deepening commercial headwinds in its core product franchises and the financial burden of its pending $14.5 billion acquisition of Penumbra Inc. The rating agency expects revenue growth to decelerate sharply through 2028, driven by setbacks in the WATCHMAN and electrophysiology franchises. S&P projects adjusted leverage to exceed its 2.5x downside trigger upon the Penumbra acquisition's close and remain elevated for at least two years, requiring careful management of reinvestment and capital allocation to stabilize credit metrics.

Nov 6, 2026

Bristol Myers Squibb's dividend, currently yielding over 4%, appears durable despite an anticipated $1.5 billion to $2 billion drop in Eliquis sales in 2027 and significant debt. The company's payout ratios are low (around 40% of earnings and 39% of free cash flow), and debt has been decreasing. While dividend growth may be slow as the company prioritizes debt reduction and business development, its long history of payments suggests resilience.

Nov 6, 2026

An investment of $1000 in AbbVie (NYSE: ABBV) stock 10 years ago would now be worth $4,635.14, based on its current price of $289.74. Over the past decade, AbbVie has delivered an average annual return of 16.33%, outperforming the market by 3.3% on an annualized basis. This demonstrates the significant impact of compounded returns on wealth growth over time.

Nov 6, 2026

Tandem Diabetes Care has appointed Jeannette Bankes, a former GE HealthCare executive, as its new President and CEO, effective November 16. Bankes will succeed John Sheridan, who plans to retire at the end of 2026 after leading the company for over a decade. Her appointment is expected to advance Tandem's technology roadmap, expand access to its products, and drive profitable growth.

Nov 6, 2026

AbbVie's stock trades at a higher multiple than the S&P 500, with its adjusted earnings multiple around 21 based on 2026 forecasts. The key factor for investors is whether its double-digit sales growth can continue, especially with a government-set price taking effect on its drug Vraylar in 2027. While Vraylar and Humira sales are declining, the company's growth largely depends on its two largest drugs, Skyrizi and Rinvoq, which are expected to contribute significantly to 2026 revenue.

Nov 6, 2026

AbbVie's stock performance is increasingly tied to the success of its two immunology treatments, Skyrizi and Rinvoq, which now account for nearly half of its total sales. These drugs are growing significantly faster than the company as a whole, offsetting declines from older drugs like Humira and Imbruvica due to competition and pricing pressures. Investors should closely monitor the proportion of AbbVie's sales derived from Skyrizi and Rinvoq, as their continued growth is crucial for the company's future performance amidst increasing market competition.